β2肾上腺素受体激动剂福莫特罗诱导线粒体生物发生加速足细胞损伤恢复
本研究探讨增加线粒体生物发生能否加速足细胞从损伤中恢复。在体外,福莫特罗增加线粒体生物发生并恢复线粒体形态和肌动蛋白骨架;在小鼠急性肾毒性血清肾炎和慢性阿霉素肾病模型中,损伤后给予福莫特罗可加速肾功能恢复、减少蛋白尿并改善病理。结果提示β2肾上腺素受体是足细胞病的新治疗靶点。
要点
- 福莫特罗通过β2肾上腺素受体增加足细胞线粒体生物发生。
- 损伤后给予福莫特罗可加速小鼠肾功能恢复并减少蛋白尿。
- β2肾上腺素受体可能是足细胞病的治疗靶点。
核心结论
- 增加线粒体生物发生可加速足细胞从损伤中恢复。
- 福莫特罗通过β2肾上腺素受体诱导线粒体生物发生,改善足细胞损伤恢复。
研究设计与样本
- 体外足细胞损伤与恢复模型,以及小鼠急性肾毒性血清肾炎和慢性阿霉素肾病模型。
- 小鼠在肾小球功能障碍确立后(损伤后)接受福莫特罗治疗。
主要发现
- 足细胞损伤与恢复过程中PGC-1α和线粒体电子传递链关键组分明显上调。
- 福莫特罗增加线粒体生物发生,恢复线粒体形态及损伤诱导的肌动蛋白骨架改变。
- 足细胞膜存在β2肾上腺素受体,其敲低减弱福莫特罗诱导的线粒体生物发生。
- 小鼠损伤后给予福莫特罗减少蛋白尿、改善肾脏病理、减少细胞凋亡,并增加PGC-1α和多个电子传递链蛋白表达。
临床怎么用
- 提示β2肾上腺素受体激动剂福莫特罗可能用于促进足细胞损伤后的恢复,但需进一步临床研究验证。
局限性
- 证据主要来自体外足细胞模型和两种小鼠模型,尚未在人体中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Podocytes have limited ability to recover from injury. Here, we demonstrate that increased mitochondrial biogenesis, to meet the metabolic and energy demand of a cell, accelerates podocyte recovery from injury. Analysis of events induced during podocyte injury and recovery showed marked upregulation of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α), a transcriptional co-activator of mitochondrial biogenesis, and key components of the mitochondrial electron transport chain. To evaluate our hypothesis that increasing mitochondrial biogenesis enhanced podocyte recovery from injury, we treated injured podocytes with formoterol, a potent, specific, and long-acting β2-adrenergic receptor agonist that induces mitochondrial biogenesis in vitro and in vivo. Formoterol increased mitochondrial biogenesis and restored mitochondrial morphology and the injury-induced changes to the organization of the actin cytoskeleton in podocytes. Importantly, β2-adrenergic receptors were found to be present on podocyte membranes. Their knockdown attenuated formoterol-induced mitochondrial biogenesis. To determine the potential clinical relevance of these findings, mouse models of acute nephrotoxic serum nephritis and chronic (Adriamycin [doxorubicin]) glomerulopathy were used. Mice were treated with formoterol post-injury when glomerular dysfunction was established. Strikingly, formoterol accelerated the recovery of glomerular function by reducing proteinuria and ameliorating kidney pathology. Furthermore, formoterol treatment reduced cellular apoptosis and increased the expression of the mitochondrial biogenesis marker PGC-1α and multiple electron transport chain proteins. Thus, our results support β2-adrenergic receptors as novel therapeutic targets and formoterol as a therapeutic compound for treating podocytopathies.
引用
- Arif E, Solanki AK, Srivastava P, et al. Mitochondrial biogenesis induced by the β2-adrenergic receptor agonist formoterol accelerates podocyte recovery from glomerular injury. Kidney Int. 2019. PMID: 31262488. doi:10.1016/j.kint.2019.03.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。